The cost effectiveness of universal antenatal screening for HIV in New Zealand

AIDS

Volumn 17, Issue 5, 2003, Pages 741-748

  Bramley, Dale ^a   Graves, Nicholas ^b   Walker, Damian ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

AIDS; Antenatal; Cost effectiveness analysis; Economic evaluation; HIV; New Zealand; Screening

Indexed keywords

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MASS SCREENING; NEW ZEALAND; PRENATAL DIAGNOSIS; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MASS SCREENING; NEW ZEALAND; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; VALUE OF LIFE;

EID: 0037471275     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00013     Document Type: Article

References (58)

1. Connor E, Sperling R. Reduction of maternal-infant transmission of HIV type I with zidovudine treatment. New Engl J Med 1994, 331:1173-1180.
2. Mofenson L, McIntyre J. Advances and research direction in the prevention of mother to child HIV-1 transmission. Lancet 2000, 355:2237-2243.
3. Rogers MF, Fowler M, Lindgren M. Revised recommendations for HIV screening in pregnancy. MMWR 2001, 50 (RR19):59-86.
4. Mofenson L. Epidemiology and determinants of vertical HIV transmission. Semin Paediatr Infect Dis 1994, 5:252-265.
5. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999, 353:1035-1039.
6. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type I. New Engl J Med 1999, 340:977-987.
7. Lallemant M, Jourdain G, Le-Coeur S. A trial of shortened zidovudine regiments to prevent mother-to-child transmission of human immunodeficiency virus type 1. New Engl J Med 2000, 343:982-991.
8. Department of Health. Reducing Mother to Baby Transmission of HIV. London: Department of Health; 1999.
9. Patrick D, Money D, Forbes J, Dobson S, Rekart M. Routine prenatal screening for HIV in a low prevalence setting. Can Med Assoc J 1998, 159:942-947.
10. Lindgren S, Bohlin A, Forsgen M. Screening for HIV -1 antibodies in pregnancy: results from the Swedish national programme. BMJ 1993, 307:1447-1451.
11. Chambers S, Heckert K, Bagshaw S, Ussher J, Birch M, Wilson M. Maternity care providers attitudes and practices concerning HIV testing during pregnancy; results of a survey of the Canterbury and upper South Island. N Z Med J 2001, 114:513-516.
12. Dickson N. HIV infection in pregnancy. N Z Med J 2001, 114:507-508.
13. Heckert K, Bagshaw A, Fursman L, Kipa M, Wilson M, Braiden V, et al. Women's acceptability of screening for HIV in pregnancy. N Z Med J 2001, 114:509-512.
14. Eberhart-Phillips J, Dickson N, Williams S, Clarke R, Fonua L, Kini GP, et al. Asking pregnant women about HIV risk [letter]. N Z Med J 1998, 111:175.
15. Bramley D, Graves N. Antenatal screening for HIV. N Z Med J 2002, 115:24.
16. Ministry of Health. HIV in Pregnancy: Risk Screening Guidelines for Health Professionals. Wellington: Ministry of Health; 1997.
17. Taylor B, Dickson N, Carter M. Third Annual Report of the New Zealand Paediatric Surveillance Unit. Dunedin: University of Otago, 2000.
18. Schrappe M, Lauterbach K. Systematic review on cost-effectiveness of public health interventions for primary HIV-prevention programmes. AIDS 1998, 12 (suppl AS):S231-S238.
19. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on the Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Human Services and Health; 1995.
20. Department of Health. Policy Appraisal and Health. London: Department of Health; 1995.
21. Culnane M, Fowler M, Lee S. Lack of long term effects of in utero exposure to zidovudine among uninfected children born to HIV infected women. JAMA 1999, 281:151-157.
22. Sperling R, Shapiro D, McSherry G. Safety of the maternal-infant zidovudine regimen utilised in the paediatric AIDS clinical trial group 076 study. AIDS 1998, 12:1805-1813.
23. Auckland Starship Hospital Protocol. Guidelines for the paediatric management of infants born to HIV positive pregnant women. Auckland: Auckland District Health; 2001:1-2.
24. Center for Disease Control and Prevention. Public Health Service Task Force Recommendations for the use of anti-retroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing peri-natal HIV-1 transmission in the United States. MMWR 1998, 47 (RR-2):1-30.
25. Brady H. Standard Protocol for Confirmation of Positive HIV Antibody Tests in New Zealand. Wellington: ESR; 2001.
26. Gibb D, MacDonagh S, Tookey P, Duong T. Uptake of interventions to reduce mother to child transmission of HIV in United Kingdom and Ireland. AIDS 1997, 11:F53-F58.
27. Richardson M, Sharland M. Late diagnosis of paediatric HIV infection in south west London. BMJ 1998, 316:271-272.
28. Ades A, Sculpher M, Gibb D. Cost effectiveness analysis of antenatal HIV screening in the United Kingdom. BMJ 1999, 319:1230-1240.
29. Postma M, Beck E, Mandalia S. Universal HIV screening of pregnant women in England: Cost-effectiveness analysis. BMJ 1999, 318:1656-1660.
30. Zaric G, Bayoumi A, Brandeau M. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Def Syndr 2000, 25:403-416.
31. Immergluck L, Cull W, Schwartz A, Elstein A. Cost effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 2000, 105:4. www.pediatrics.org/cgi/content/full/105/4/e54
32. Croxson BE, Ashton T. A cost-effectiveness analysis of the treatment of end stage renal failure. N Z Med J 1990, 103:171-174.
33. Szeto KL, Devlin NJ. The cost effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health Policy 1996, 38:101-115.
34. Hansen P, Scuffham PA. The cost effectiveness of compulsory bicycle helmets in New Zealand. Austral J Publ Health 1995, 19:450-454.
35. Surrey Advertiser. Patients' lives 'are given a price'. Guilford: Surrey Advertiser; 01 February 2002.
36. Action on Smoking and Health. Bupropion and NRT to promote smoking cessation. Action on Smoking and Health; 2001. http://www.ash.org.uk/html/cessation/nicesummary.html
37. Laupacis A, Feeney D, Detsky AS, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J 1992, 146:4:473-481.
38. Owens D. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998, 13:716-717.
39. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursements in Australia. Pharmacoeconomics 2001, 19:1103-1109.
40. Hirth RA, Chernew ME, Miller E, Fendrick M, Weussert WG. Willingness to pay for a quality adjusted life year: in search of a standard. Medical Decision Making 2000, 20:3:332-342.
41. The Worldbank. 2000. http://www.worldbank.org/
42. Statistics New Zealand. 2000. http://www.stats.govt.nz/
43. Lewis R, O'Brien J, Ray D, Sibai B. The impact of initiating a human immunodeficiency virus screening programme in an urban obstetric population. Am J Obstet Gynecol 1995, 173:1329-1333.
44. Lindsey M, Feng T, Peterson H, Slate B. Routine human immunodeficiency virus screening in unregistered and registered inner city patients. Obstet Gynecol 1991, 77:599-603.
45. Cozen W, Mascola L, Enguidanos R, Bauch S, Giles M. Screening for HIV and Hepatitis B in Los Angeles County prenatal clinics. J Acquired Immune Defic Syndr 1993, 6:95-98.
46. Faden R, Gielen A, Kass N, O'Campo P, Anderson J. Prenatal HIV antibody testing and the meaning of consent. AIDS Public Policy J 1994, 9:151-159.
47. Barbacci M, Repke J. Routine prenatal screening for HIV infection. Lancet 1991, 337:709-711.
48. Croxson K. False Positive Rate for HIV Antibody Testing in the Blood Donor Population in New Zealand. Auckland: Auckland District Health Board; 2001.
49. Mofenson LM, Lambert JS, Stiehm ER. Risk factors of perinatal transmission of human immunodeficiency virus type 1 in women treated with Zidovudine. N Engl J Med 1999, 341:385-393.
50. Statistics New Zealand. Profile of New Zealanders. Life expectancy 1996. 2001. www.stats.govt.nz
51. Mauskopf J, Paul J, Wichman D. Economic impact of treatment of HIV positive pregnant women and their newborns with zidovudine. J Am Med Assoc 1996, 276:132-138.
52. Simpson W, Johnstone F, Goldberg D, Gormley S, Hart G. Antenatal HIV testing: assessment of a routine voluntary approach. BMJ 1999, 318:1660-1661.
53. Chrystie I, Wolfe C, Kennedy J, Zander L, Tilzey A, Banatvala L. Voluntary named testing for HIV in a community based antenatal clinic: a pilot study. BMJ 1995, 311:928-931.
54. Richardson M, Sharland M. Late diagnosis of paediatric HIV infection in south west London. BMJ 1998, 316:271-272.
55. Auckland District Health Board Finance Department. Cost of HIV Investigations. 2001.
56. Pharmac. Pharmac Interactive Drug Schedule. www.pharmac.govt.nz/interactive/scripts/index.asp
57. Counties Manukau District Health Board - Finance Department. Cost of Investigations. 2001.
58. Diagnostic Medlab. Cost Pricing for HIV Related Lab Tests. Auckland: Diagnostic Medlab; 2001.